Back to top
more

Myriad Genetics (MYGN)

(Delayed Data from NSDQ)

$18.18 USD

18.18
518,695

+0.20 (1.11%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $18.17 -0.01 (-0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Bio-Techne (TECH) Beats Earnings, Revenue Estimates in Q4

Bio-Techne (TECH) rides high on strength in all three segments in Q4. Also, the company is focusing on product innovation through research and development.

    Myriad Genetics (MYGN) Beats on Q4 Earnings & Revenues

    Myriad Genetics (MYGN) rides high on strength in Molecular diagnostics with significant contributions from GeneSight. Also, hereditary cancer testing continues to witness sequential growth.

      Can Myriad Genetics (MYGN) Spring a Surprise in Q4 Earnings?

      Myriad Genetics (MYGN) is well poised to deliver favorable results in Q4 riding on a diversified portfolio with products like Vectra DA test.

        Myriad Genetics to Grow with Study Successes, New Alliances

        On Jul 6, we issued an updated research report on Myriad Genetics, Inc. (MYGN).

          Myriad Genetics (MYGN) Catches Eye: Stock Moves Up 5.7%

          Myriad Genetics, Inc. (MYGN) moved big last session, as its shares rose over 5% on the day.

            Myriad Genetics BRACAnalysis CDx in OlympiAD Results Positive

            Myriad Genetics, Inc. (MYGN), a leading molecular diagnostics and personalized medicine company recently unveiled positive data pertaining to its BRACAnalysis CDx test.

              Why Is Myriad Genetics (MYGN) Down 9.6% Since the Last Earnings Report?

              Myriad Genetics (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                Myriad Genetics Gets Extended Coverage for Prolaris Test

                Molecular diagnostics and personalized medicine major Myriad Genetics, Inc. (MYGN) recently received extended Medicare coverage for its Prolasis test.

                  Myriad Genetics (MYGN) Tops Q3 Earnings & Sales, Tweaks View

                  Myriad Genetics Inc. (MYGN) reported adjusted earnings per share (EPS) of 27 cents in the third quarter of fiscal 2017, down 34% year over year.

                    Can Myriad Genetics (MYGN) Spring a Surprise in Q3 Earnings?

                    Myriad Genetics, Inc. (MYGN) is scheduled to report third-quarter fiscal 2017 results on May 2, after the closing bell.

                      Myriad Genetics (MYGN) Launches EndoPredict Test in the US

                      Myriad Genetics, Inc. (MYGN), a leading name in the molecular diagnostics space, recently launched the EndoPredict test in the U.S. for patients with ER+ HER2 -- early-stage breast cancer.

                        Why Is Myriad Genetics (MYGN) Up 15.8% Since the Last Earnings Report?

                        Myriad Genetics (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                          Myriad Genetics (MYGN): Q2 Impressive, 2017 View a Drag

                          On Feb 8, we issued an updated research report on Salt Lake City, UT-based molecular diagnostic company Myriad Genetics Inc. (MYGN).

                            Myriad Genetics (MYGN) Beats on Q2 Earnings, Narrows View

                            Myriad Genetics Inc. (MYGN) reported adjusted earnings per share (EPS) of 26 cents in the second quarter of fiscal 2017, down 42.2% year over year.

                              Implied Volatility Surging for Myriad Genetics (MYGN) Stock Options

                              Investors in shares of Myriad Genetics, Inc. (MYGN) need to pay close attention to the stock based on moves in the options market lately.

                                Myriad Genetics (MYGN) Q2 Earnings: What's in the Cards?

                                Myriad Genetics, Inc.(MYGN) is expected to report second-quarter fiscal 2017 results on Feb 7, after the closing bell.

                                  Myriad Genetics: Evidence Street Reviews EndoPredict Test

                                  Myriad Genetics, Inc. (MYGN) recently announced that Blue Cross Blue Shield Association's technical assessment provider Evidence Street has reviewed its EndoPredict assay.

                                    Myriad Genetics' Unit Releases Favorable Data on Vectra DA

                                    Myriad Genetics, Inc.'s (MYGN) subsidiary, Crescendo Bioscience released favorable data on the use of Vectra DA to predict treatment response in patients with rheumatoid arthritis (RA).

                                      Myriad Genetics: United Rheumatology Selects Vectra DA Test

                                      Myriad Genetics, Inc.'s (MYGN) subsidiary, Crescendo Bioscience's Vectra DA assay has been added by United Rheumatology to its clinical practice guidelines for adults with rheumatoid arthritis.

                                        Will Endopredict Win Myriad's (MYGN) Genomic Testing War?

                                        Myriad Genetics (MYGN) released favorable study results demonstrating the superiority of EndoPredict test over Oncotype Dx on long-term recurrence of breast cancer.